Caribou Biosciences, Inc. Contract with Customer, Asset, after Allowance for Credit Loss, Current
Caribou Biosciences, Inc. (CRBU) had Contract with Customer, Asset, after Allowance for Credit Loss, Current of $603.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:ContractWithCustomerAssetNetCurrent · last filed 2026-08-13
- 2026-06-30: Contract with Customer, Asset, after Allowance for Credit Loss, Current $603.00K.
- 2026-03-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $691.00K.
- 2025-12-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $1.01M.
- 2025-09-30: Contract with Customer, Asset, after Allowance for Credit Loss, Current $860.00K.
| Period end | Contract with Customer, Asset, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $603.00K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $691.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.01M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $860.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $753.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $808.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.16M 10-K · filed 2026-03-05 |
| 2024-09-30 | $798.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $972.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | $971.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.43M 10-K · filed 2025-03-10 |
| 2023-09-30 | $1.66M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.48M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.64M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $2.25M 10-K · filed 2024-03-11 |
| 2022-09-30 | $1.90M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $2.09M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.49M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.49M 10-K · filed 2023-03-09 |
| 2021-09-30 | $1.85M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $830.00K 10-Q · filed 2021-09-02 |
| 2020-12-31 | $1.33M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |